Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Suzette Blanchard

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Contemporary Clinical Trials|October 7, 2010
Toxicity equivalence range design (TEQR): a practical Phase I designM Suzette Blanchard, Jeffrey A Longmate
The Journal of Biological Chemistry|June 16, 2009
The 3'-flap pocket of human flap endonuclease 1 is critical for substrate binding and catalysisL David Finger, M Suzette Blanchard, Carla A Theimer, et al.
Cancer Gene Therapy|September 8, 2020
Feasibility of intracerebrally administering multiple doses of genetically modified neural stem cells to locally produce chemotherapy in glioma patientsJana Portnow, Behnam Badie, M Suzette Blanchard, et al.
Blood Advances|September 7, 2021
CD19-directed CAR T-cell therapy for treatment of primary CNS lymphomaTanya Siddiqi, Xiuli Wang, M Suzette Blanchard, et al.
JAMA Oncology|October 8, 2020
Systemic Anti-PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal FluidJana Portnow, Dongrui Wang, M Suzette Blanchard, et al.
The Oncologist|December 11, 2014
Age-related changes in nanoparticle albumin-bound paclitaxel pharmacokinetics and pharmacodynamics: influence of chronological versus functional ageArti Hurria, M Suzette Blanchard, Timothy W Synold, et al.
Cancer Chemotherapy and Pharmacology|January 9, 2015
A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridineEdward M Newman, Robert J Morgan, Shivaani Kummar, et al.
Journal of Geriatric Oncology|March 5, 2021
Phase II study of neratinib in older adults with HER2 amplified or HER2/3 mutated metastatic breast cancerYuan Yuan, Jin Sun Lee, Susan E Yost, et al.
Cell Reports. Medicine|August 16, 2025
Chlorotoxin-directed CAR T cell therapy for recurrent glioblastoma: Interim clinical experience demonstrating feasibility and safetyMichael E Barish, Maryam Aftabizadeh, Jonathan Hibbard, et al.
Stem Cells Translational Medicine|September 10, 2013
Magnetic resonance imaging tracking of ferumoxytol-labeled human neural stem cells: studies leading to clinical useMargarita Gutova, Joseph A Frank, Massimo D'Apuzzo, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Contemporary Clinical Trials|October 7, 2010
Toxicity equivalence range design (TEQR): a practical Phase I designM Suzette Blanchard, Jeffrey A Longmate
The Journal of Biological Chemistry|June 16, 2009
The 3'-flap pocket of human flap endonuclease 1 is critical for substrate binding and catalysisL David Finger, M Suzette Blanchard, Carla A Theimer, et al.
Cancer Gene Therapy|September 8, 2020
Feasibility of intracerebrally administering multiple doses of genetically modified neural stem cells to locally produce chemotherapy in glioma patientsJana Portnow, Behnam Badie, M Suzette Blanchard, et al.
Blood Advances|September 7, 2021
CD19-directed CAR T-cell therapy for treatment of primary CNS lymphomaTanya Siddiqi, Xiuli Wang, M Suzette Blanchard, et al.
JAMA Oncology|October 8, 2020
Systemic Anti-PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal FluidJana Portnow, Dongrui Wang, M Suzette Blanchard, et al.
The Oncologist|December 11, 2014
Age-related changes in nanoparticle albumin-bound paclitaxel pharmacokinetics and pharmacodynamics: influence of chronological versus functional ageArti Hurria, M Suzette Blanchard, Timothy W Synold, et al.
Cancer Chemotherapy and Pharmacology|January 9, 2015
A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridineEdward M Newman, Robert J Morgan, Shivaani Kummar, et al.
Journal of Geriatric Oncology|March 5, 2021
Phase II study of neratinib in older adults with HER2 amplified or HER2/3 mutated metastatic breast cancerYuan Yuan, Jin Sun Lee, Susan E Yost, et al.
Cell Reports. Medicine|August 16, 2025
Chlorotoxin-directed CAR T cell therapy for recurrent glioblastoma: Interim clinical experience demonstrating feasibility and safetyMichael E Barish, Maryam Aftabizadeh, Jonathan Hibbard, et al.
Stem Cells Translational Medicine|September 10, 2013
Magnetic resonance imaging tracking of ferumoxytol-labeled human neural stem cells: studies leading to clinical useMargarita Gutova, Joseph A Frank, Massimo D'Apuzzo, et al.
Pageof 2